Management of Chronic Cerebral Microhemorrhages
Chronic cerebral microhemorrhages (CMHs) identified on MRI should be managed conservatively with observation and risk factor modification, not surgical intervention, as they represent markers of underlying small vessel disease rather than lesions requiring treatment. 1
Key Distinction: Microhemorrhages vs. Cavernous Malformations
The provided evidence primarily addresses cavernous malformations (CCMs/CMs), which are distinct vascular lesions with a characteristic "popcorn" appearance and hemosiderin ring on MRI. True chronic microhemorrhages are small foci of hemosiderin deposition (typically <10mm) visible only on gradient-echo or susceptibility-weighted imaging sequences 2.
Differential Diagnosis Considerations
When evaluating small hemorrhagic lesions on MRI, distinguish between:
- Cavernous malformations: Classic "popcorn" appearance with hemosiderin ring on T2-weighted imaging 1
- Cerebral microbleeds: Small (<10mm) foci visible only on gradient-echo/SWI sequences, associated with:
Multiple tiny hemorrhagic lesions without typical CM features are more likely cerebral microbleeds rather than cavernous malformations 1.
Management Algorithm
1. Initial Assessment
Determine the underlying etiology:
- Location pattern: Deep/basal ganglia suggests hypertensive vasculopathy; strictly lobar/cortical suggests cerebral amyloid angiopathy 5, 4
- Number: Small numbers (<5) have different implications than extensive burden 6
- Clinical context: Age, hypertension, cognitive symptoms, prior hemorrhage 3, 4
- Family history: Multiple affected relatives or multifocal lesions without developmental venous anomaly suggest familial cavernous malformation requiring genetic testing 1
2. Imaging Recommendations
For suspected cavernous malformations:
- Brain MRI with gradient-echo or susceptibility-weighted sequences is the diagnostic standard (Class I, Level B) 2
- Catheter angiography is NOT recommended unless arteriovenous malformation is in the differential (Class III, Level C) 2
Follow-up imaging is indicated only for:
- New or worsening neurological symptoms 2
- Changed or worsening seizures 2
- Changes in neurological examination 2
Routine surveillance imaging intervals are not well-established and should be based on clinical judgment 1. Asymptomatic lesions do not require scheduled follow-up imaging.
3. Conservative Management Strategy
Asymptomatic microhemorrhages/small cavernous malformations:
- Conservative management is advocated (Class 2a, Level C-LD) 2, 1
- The benign progression of incidental lesions with minimal hemorrhage risk generally precludes prophylactic surgery 1
- Multiple small lesions visible only on gradient-echo/SWI do not necessarily correlate with worse clinical outcome 2
4. Risk Factor Modification
Address modifiable vascular risk factors:
- Blood pressure control: CMH burden correlates significantly with mean arterial pressure 7, 8
- Hypertension management is critical as it directly influences microhemorrhage formation 7, 8
- Control of other cardiovascular risk factors (smoking cessation, lipid management) 4
5. Antithrombotic Therapy Considerations
Critical decision point for patients requiring anticoagulation or antiplatelet therapy:
Small numbers of microhemorrhages (<5) do NOT contraindicate intravenous thrombolysis (Level B evidence) 6. However:
- Lobar location (suggesting cerebral amyloid angiopathy) poses higher recurrence risk with anticoagulation 9
- Advanced age, degree of anticoagulation, leukoaraiosis, and presence of microbleeds on MRI increase hemorrhage risk 9
- Recent evidence shows anti-thrombotic treatment was not associated with increased CMH prevalence in cognitively asymptomatic adults 10
For patients with compelling indications for anticoagulation:
- Weigh individual hemorrhagic vs. thrombotic risk based on location, number, and underlying pathology 9
- Consider intravenous heparin (PTT 1.5-2.0x normal) or LMWH as potentially safer acute options than warfarin 9
- Avoid bolus heparin therapy due to increased bleeding risk 9
6. Surgical Intervention
Surgery is NOT indicated for asymptomatic microhemorrhages or incidental small cavernous malformations 2, 1.
Consider surgical resection only for symptomatic cavernous malformations with:
- Recurrent symptomatic hemorrhages
- Medically refractory seizures
- Progressive neurological deficits
- Accessible location with acceptable surgical risk 2, 1
Evidence for surgical benefit remains conflicting, with no high-quality studies showing dramatic benefit 2. One study showed poorer outcomes and higher risk of symptomatic bleeds in the surgical group compared to conservative management 2.
Common Pitfalls to Avoid
Do not over-interpret technical artifacts: Higher field strength MRI and gradient-echo sequences cause lesions to appear larger and more numerous than they actually are 2
Avoid alarming terminology: Terms like "too numerous to count" have dramatic psychological impact on patients; use estimates instead (e.g., "approximately 20-30 small lesions") 2
Do not withhold necessary antithrombotic therapy based solely on microhemorrhage presence: Small numbers (<5) do not contraindicate treatment in acute ischemic stroke 6
Do not perform routine surveillance imaging: Repeat imaging should be symptom-driven, not scheduled 2, 1, 2
Recognize that subclinical imaging changes may occur without clinical significance: Not all MRI changes constitute symptomatic hemorrhage events 1
Prognostic Implications
Higher microhemorrhage burden predicts:
- Increased risk of future symptomatic intracerebral hemorrhage (particularly in lobar locations with cerebral amyloid angiopathy) 11
- Recurrent disabling or fatal strokes (primarily ischemic) 12
- Cognitive impairment and loss of independent functioning 11
- Executive dysfunction in ischemic cerebrovascular disease 4
The total number of hemorrhages at baseline correlates with these risks, with 3-year cumulative ICH risks of 14%, 17%, 38%, and 51% for patients with 1,2,3-5, or ≥6 baseline hemorrhages respectively 11.